- Home
- RMNI vs AVIR Comparison
RMNI vs AVIR Comparison
Compare RMNI & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMNI | AVIR |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.2M | 318.0M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RMNI | AVIR |
|---|---|---|
| Price | $3.12 | $5.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.50 | ★ $8.00 |
| AVG Volume (30 Days) | 377.5K | ★ 574.1K |
| Earning Date | 04-30-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 197.50 | 3.00 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $431,496,000.00 | $351,367,000.00 |
| Revenue This Year | $6.02 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | ★ 5.33 | N/A |
| 52 Week Low | $2.87 | $2.46 |
| 52 Week High | $5.38 | $6.45 |
Technical Indicators
Market Signals| Indicator | RMNI | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 33.72 | 60.65 |
| Support Level | $3.02 | $3.33 |
| Resistance Level | $4.14 | $6.45 |
| Average True Range (ATR) | 0.13 | 0.34 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 2.19 | 58.86 |
Price Performance
Historical ComparisonAbout RMNI Rimini Street Inc. (DE)
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, databases, and technology software platforms. The company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management, database, and technology software systems. Geographically, the company generates its revenue from the United States of America and the International market.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).